CRISPR-Cas9: A new approach to genome editing and clinical treatment
The development of clustered short palindromic repeats within the CRISPR/Cas system for genome editing has opened up new possibilities for direct targeting and modification of genome sequences in all eukaryotic cells. This opens up new perspectives in the field of biotechnology and new treatment options for human diseases. The year 2012 was of crucial importance, as at that time CRIPSR-Cas9 was introduced in an interesting way, which gave hope to patients with inherited diseases, as more competent work was now being done to improve various strategies and models of the CRISPR-Cas system. The CRISPR-Cas9 genome editing system, its applications for treatment and delivery, and future prospects are summarized in this review. Although there are still concerns about the efficiency and safety of this method, its success cannot be denied, nor can the fact that genome editing in this way will soon be used in clinical practice, making the work and the treatment itself much easier.
How to Cite
Copyright (c) 2022 Ilma Meša
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
This journal permits and encourages authors to post items/PDFs submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.